Diabetes Research and Clinical Practice
Volume 57, Issue 1 , Pages 35-43 , July 2002

Incidence of diabetic nephropathy in Type 1 diabetic patients in Spain: ‘Estudio Diamante’

  • E. Esmatjes

      Affiliations

    • Diabetes Unit, Hospital Clı́nic Universitari, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Villarroel 170, 08036 Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel./fax: +34-93-2275411
    • ,
  • F. De Alvaro

      Affiliations

    • Nephrology Unit, Hospital Universitario La Paz, Madrid, Spain
    • ,
  • for the ‘Estudio Diamante’, investigators

Received 3 July 2001 ,Revised 22 October 2001 ,Accepted 2 January 2002.

References 

  1. Mogensen CE, Schmitz O. The diabetic kidney: from hyperfiltration and microalbuminuria to end-stage renal failure. Med. Clin. N. Am. 1988;72:1465–1492
  2. Parving HH, Hommel E, Mathiesen E, Skott P, Edsberg B, Bahnsen M, et al. Prevalence of microalbuminuria, arterial hypertension retinopathy and neuropathy in patients with insulin dependent diabetes. Br. Med. J. 1988;296:156–160
  3. Orchard TJ, Dorman JS, Maser RE, et al.  Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology Diabetes Complication Study II. Diabetes. 1990;39:1116–1124
  4. Microalbuminuria Collaborative Study Group UK. Microalbuminuria in Type 1 diabetic patients. Diabetes Care. 1992;15:495–501
  5. EURODIABIDDM Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994;37:278–285
  6. Mathiesen ER, Oxenboll B, Johansen K, Svendsen PA, Deckert T. Incipient nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia. 1984;24:406–410
  7. The EURODIAB IDDM Complication Study Group Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R. Blood pressure, retinopathy and urinary albumin excretion in IDDM: the EURODIAB IDDM Complications study. Diabetologia. 1995;38:599–603
  8. Estudio Diamante, Renal involvement in type 1 (IDDM) diabetes in Spain. Diabetes Res. Clin. Pract. 38 (1997) 129–137.
  9. Jury DR, Mikkelsen DJ, Dunn PJ. Prozone effect and the immunoturbidimetric measurements of albumin in urine. Clin. Chem. 1990;36:1518–1522
  10. Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P. Laser immunonephelometry for routine quantification of urinary albumin excretion. Clin. Chem. 1987;33:209–214
  11. Mathiesen ER, Ronn B, Jensen T, Storm B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes. 1990;39:245–249
  12. The Microalbuminuria Collaborative Study Group. Predictors of development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabetic Med. 1999;16:918–925
  13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–982
  14. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60:219–227
  15. Wiseman MJ, Viberti GC, Mackintosh D, Jarret RJ, Keen H. Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1984;26:402–405
  16. Hasslacher CH, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia. 1985;28:6–11
  17. Jerums G, Allen TJ, Tsalamandris C, Akdeniz A, Sinha A, Gilbert R, et al. Relationship of progressively increasing albuminuria to apoprotein (a) and blood pressure in type-2 (non-insulin-dependent) and type-1 (insulin-dependent) diabetic patients. Diabetologia. 1993;36:1037–1044
  18. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, et al. Predictors of microalbuminuria in individuals with IDDM. Diabetes Care. 1993;16:1373–1383
  19. Gatling W, Mullee MA, Knigh C, Hill RD. Microalbuminuria in diabetes: relationship between urinary albumin excretion and diabetes-related variables. Diabetic Med. 1988;5:348–351
  20. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipedemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. 1999;56(Suppl. 71):S31–S36
  21. Chase HP, Garg SK, Marshall G, Berg LC, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with Type 1 diabetes. J. Am. Med. Assoc. 1991;265:614–617
  22. Mühlhauser I, Sawicki P, Berger M. Cigarette smoking as a risk factor for macroalbuminuri and proliferative retinopathy in type 1 diabetes. Diabetologia. 1986;29:500–502
  23. West KM, Erdreich LS, Stober JA. Absence of a relationship between smoking and diabetic microangiopathy. Diabetes Care. 1980;3:250–252
  24. Hansen HP, Rossing K, Jacobsen P, Jensen BR, Parving HH. The acute effect of smoking on systemic haemodynamics, kidney and endothelial functions in insulin-dependent diabetic patients with microalbuminuria. Scand. J. Clin. Invest. 1996;56:393–399
  25. Morrow J, Frei B, Longmire A, Graziano J, Lynch S, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N. Engl. J. Med. 1995;332:1198–1203
  26. Esmatjes E, Flores L, Lario S, Claria J, Cases A, Iñigo P, et al. Smoking increases serum levels of transforming growth factor-β in diabetic patients. Diabetes Care. 1999;22:1915–1916

PII: S0168-8227(02)00007-4

Diabetes Research and Clinical Practice
Volume 57, Issue 1 , Pages 35-43 , July 2002

Article Tools